Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PRKX | P51817 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2382554 | 1.00 | CYP19A1 (0.40) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3183323 | 1.00 | CYP19A1 (0.40) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL6579025 | 0.89 | CYP3A4 (0.38) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1516192 | 0.81 | CYP3A4 (0.42) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL6480804 | 0.81 | CYP3A4 (0.42) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL348431 | 0.81 | CYP3A4 (0.42) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| 1-(4-Pyridyl)-1-Butanol SCHEMBL4956036 | 0.80 | CYP51A1 (0.43) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| 1-(4-Pyridyl)-1-Butanol SCHEMBL13909751 | 0.80 | CYP51A1 (0.43) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL31676679 | 0.79 | SLC6A2 (0.39) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 | |
| 1-(4-Pyridyl)-1-Butanol SCHEMBL8606540 | 0.78 | CYP51A1 (0.42) | CYP19A1CYP3A4CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556398-B1 | NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-7553826-B2 | Cytarabine monophosphate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20070037774-A1 | Cytarabine monophosphate (araCMP) cyclic diesters of 1,3 propane-1-(4-pyridyl) diols that (5'-O-cis-[4-(4-pyridyl)-1,3,2-dioxaphosphorin-2-oxo-2-yl]-cytosine-beta -D-arabinofuranoside); liver cancer; liver disorders; liver viral infections; activates cytochrome P450; side effect reduction; half-life | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2007-02-15 | — | — | US | disclosed |
| US-7151092-B2 | Cytarabine monophosphate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| EP-1556398-A1 | NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004041837-A1 | NOVEL CYTARABINE MONOPHOSPHATE PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092476-A1 | Novel cytarabine monophosphate prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092476-A1 | Novel cytarabine monophosphate prodrugs | TYMP, CDA, PNP | CYP19A1 1199/4885CYP3A4 95/4885CYP17A1 2842/4885 |
| US-20070037774-A1 | Cytarabine monophosphate (araCMP) cyclic diesters of 1,3 propane-1-(4-pyridyl) diols that (5'-O-cis-[4-(4-pyridyl)-1,3,2-dioxaphosphorin-2-oxo-2-yl]-cytosine-beta -D-arabinofuranoside); liver cancer; liver disorders; liver viral infections; activates cytochrome P450; side effect reduction; half-life | TYMP, CDA, PNP | CYP19A1 996/4885CYP3A4 80/4885CYP17A1 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.